Greetings from ST Pharm’s CEO, Moo Je Sung! Mooje Sung was appointed as the new CEO of ST PHARM. Having worked at Novartis for 20 years, Dr. Sung is one of the co-developers of the FDA-approved breast cancer treatment Kisqali. We look forward to our bright future of innovative medicine and drug development with Dr. Sung at the forefront. Please show him your warmest greetings and stay tuned with our updates to see how our organization continues to grow and flourish under CEO Sung’s valuable expertise. #STPharm #Innovation #Science #CDMO
소개
“ST Pharm provides reliable and timely custom manufacturing services for API following stringent quality system and close communication with the clients.” Founded in 1983, ST Pharm (formerly known as Samchully Pharmaceutical) has been offering excellent custom manufacturing services of APIs and their intermediates to meet clients’ high expectation for their use in pharmaceutical development in compliant to cGMP requirements. Our reliability in service, which is well-proven through decades of business relationship with many big pharmas and biotech clients, is the essence of our strength along with our expertise in process development and scale-up optimization. Historically, ST Pharm has been focusing our expertise on nucleoside based active pharmaceuticals in various antiviral drug applications; we became the world largest supplier of Thymidine in the late 1990s and Zidovudine in the mid 2000s and protected nucleosides in the early 2000s. ST Pharm has continuously been expanding its service offering, including synthesis of therapeutic oligonucleotides. In June 2010, ST Pharm became a subsidiary of Dong-A Pharmaceutical, the top pharmaceutical company in Korea. ST Pharm is committed to expanding its business scope into generic APIs and their intermediates with full support and collaboration with parent company Dong-A Pharmaceutical.
- 웹사이트
-
https://www.stpharm.co.kr/en
에스티팜 외부 링크
- 업계
- 제약
- 회사 규모
- 직원 501 - 1,000명
- 본사
- Seoul
- 유형
- 상장기업
- 설립
- 1983
- 전문 분야
- New Drug APIs & Intermediates (Anti HCV/HIV/AIDS), Generic APIs & Intermediates (Anti-Viral Cancer Coagulant hypertensive), Oligonucleotides & Amidites & Nucleoside Monomers (Anti-Cancer) 및 mRNA CDMO (5'-cap, LNP)
위치
에스티팜 직원
업데이트
-
🌟 Happy New Year! As we step into a brand-new year, we reflect on the milestones achieved in 2024 and look forward to the exciting opportunities that 2025 holds for ST PHARM. Our commitment to driving pharmaceutical innovation, empowering healthier lives, and building stronger partnerships remains unwavering. None of this would be possible without our dedicated team and valued collaborators. Here’s to a year filled with progress, success, and shared accomplishments. Wishing everyone a prosperous and inspiring 2025 as we continue this journey together! #STPHARM #HappyNewYear #Pharmaceutical #Innovation
-
🙏 What are you thankful for in 2024? As we reflect on the past year, we’re grateful for the partnerships, collaborations, and innovations that have driven us forward. This Thanksgiving, we want to extend our heartfelt thanks to our incredible team, partners, and clients for their continued support and dedication. Wishing everyone a happy, healthy, and peaceful holiday season. #HappyThanksgiving #STPHARM #Pharmaceutical #Innovation #CDMO
-
-
🔔 Excited to attend #EUROTIDES2024? Don’t miss our VP of Strategic Innovation, Dr. Jale Müslehiddinoğlu, on November 13 at 1:25 pm as she shares insights on advancing oligonucleotide development. Visit ST PHARM at #BOOTH801 and catch our company presentation on November 12 at 12:00 pm, where we'll be sharing our latest updates. #TIDES2024 #TidesEurope #Hamburg #STPHARM #Oligonucleotide #mRNA #CDMO
-
-
🚀 Join us at #Eurotides2024 in Hamburg, Germany, from November 12-14! On November 13 at 1:25 PM, Dr. Jale Müslehiddinoğlu, VP of Strategic Innovation, will present insights on how Quality by Design (QbD) principles, including first principles and data-driven approaches, enhance oligonucleotide process characterization. As a leading expert in oligonucleotide development and technical operations, Dr. Jale Müslehiddinoğlu will share valuable strategies to advance oligonucleotide development. While you're at the event, be sure to visit ST PHARM at #BOOTH801, and don't miss our company presentation at noon on November 12. #STPHARM #TIDES2024 #TidesEurope #Oligonucleotide #mRNA #CDMO
이 콘텐츠는 여기에서 사용할 수 없습니다.
LinkedIn 앱에서 이 콘텐츠 등 이용하기
-
🌟 Join us at #CPHIMilan! Visit us at #Booth24D31 in the Integrated Pharma Zone to discuss the future of pharma! Explore cutting-edge insights from ST Pharm’s RNA experts on service offerings, technical capabilities, RNA market trends, next-generation technology, RNA therapeutics, and more. 🌟 Special Events: ◾ Free Gelato 🍦 : daily from 15:00 to 17:00 ◾ Raffle Draws🎁 : October 8-9 at 16:00 / October 10 at 14:00 Don’t miss out on these exciting opportunities, including chances to win Samsung Electronics products! 😉 Looking forward to seeing you there! #STPHARM #Innovation #mRNA #RNA #CDMO #SouthKoreaCDMO
-
-
에스티팜님이 퍼감
I am happy to attend OTS meeting in Montreal! We will present the poster and booth. ST Pharm folks are ready to support your programs for monomers, oligos, and mRNA. I am looking forward to meeting you all. Thanks.
-
-
🚀 Exciting news! ST PHARM will be attending the 20th Annual Meeting of the Oligonucleotide Therapeutics Society from October 6 to 9 in Montreal, Canada. Join us at Booth 3-16, where we will be sharing our latest advancements in manufacturing and analysis for oligonucleotides and mRNA. We can't wait to see you there! #Oligonucleotides #mRNA #STPharm #OTS2024 #Montreal
-
-
Did you enjoy the networking event at ChemOutsourcing 2024? 에스티팜 had a successful day and met new friends from the global pharma industry. Our speech topic was “How Our Long Journey of Nucleoside Chemistry Meets CRISPR Cas,” and we were able to present ST Pharm and our RNA technology platform to the audience. During the speech, our principal manager from the Business Department, HJ (Hyuk-jun) Jung, shared his insights on RNA markets and related market forecasts, as well as ST Pharm’s technology history. Please remember that ST Pharm’s CDMO service, based on its extensive knowledge and technical platform leading to RNA, will streamline your processes in the most optimized way. #STPharm #SmallMolecule #CDMO #ChemOutsourcing #SouthKorea #TechnologyDriven #RNACDMO #NucleosideChemistry
-
-
🚀 Are you heading to #CPHIMilan ? ST PHARM is excited to participate in the 35th CPHI Worldwide in Milan from October 8th to 10th! Join us at #Booth24D31 in the Integrated Pharma Zone, where we’ll be showcasing our latest innovations and connecting with over 2,400 exhibitors and 62,000 attendees from 166+ countries. Let’s discuss the future of pharma! Explore cutting-edge insights from ST Pharm’s RNA experts on service offerings, technical capabilities, RNA market trends, next-generation technology, #RNA therapeutics, and more. For any inquiries, please contact : info@stpharm.co.kr Looking forward to seeing you there! #CPHIMilan #Innovation #mRNA #STPharm #CDMO #SouthKoreaCDMO
이 콘텐츠는 여기에서 사용할 수 없습니다.
LinkedIn 앱에서 이 콘텐츠 등 이용하기